论文著作：
1. Sheng W, Geng J, Li L, Shang Y, Jiang M, Zhen Y*. An albuminbinding domain and targeting peptidebased recombinant protein and its enediyneintegrated analogue exhibit directional delivery and potent inhibitory activity on pancreatic cancer with Kras mutation. Oncol Rep (Engl). 2020, 43(3): 851-863.
2. Geng J, Wang Y, Zhang L, Wang R, Li C, Sheng W*, et al. The cajanine derivative LJ101019C regulates the proliferation and enhances the activity of NK cells via Kv1.3 channel-driven activation of the AKT/mTOR pathway. Phytomedicine (Engl). 2020, 66(1): 153113.
3. Sheng W, Gong J, Jiang M, Zhen Y*, et al. A recombinant scFv and NGR motif-integrated fusion protein that bi-targets EGFR/CD13 inducing apoptosis and blocking tube formation, Oncol Rep (Engl). 2017, 38(12): 3507-3514.
4. Sheng W, Shang Y Li L, Zhen Y*, et al. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity. Anti-cancer Drugs (Engl). 2014, 25(1): 82-91.
5. Sheng W, Shang Y, Miao Q, Zhen Y*, et al. Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue that are directed against epidermal growth factor receptor. Anti-cancer Drugs (Engl). 2012, 23(4): 406-415.
盛唯瑾
北京市
研究领域：
生物医药
研究方向：
1.抗肿瘤重组蛋白；2.抗体药物偶联物；3.肿瘤免疫治疗药物
所在单位：
中国医学科学院北京协和医学院
